サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ヒュミラ・バイオシミラー市場：製品別、適応症別、国別、地域別- 産業分析、市場規模、市場シェア、2023-2030年予測
市場調査レポート
商品コード
1358235

ヒュミラ・バイオシミラー市場：製品別、適応症別、国別、地域別- 産業分析、市場規模、市場シェア、2023-2030年予測

Humira Biosimilar Market, By Product, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 303 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.36円
ヒュミラ・バイオシミラー市場：製品別、適応症別、国別、地域別- 産業分析、市場規模、市場シェア、2023-2030年予測
出版日: 2023年10月01日
発行: AnalystView Market Insights
ページ情報: 英文 303 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

レポートのハイライト

ヒュミラのバイオシミラー市場規模は2022年に7億9,010万米ドル、2023年から2030年にかけてCAGR 20.9%で拡大

ヒュミラ・バイオシミラー市場- 市場力学：

  • 自己免疫疾患の流行と生物学的治療に対する需要の高まり
  • ヒュミラのバイオシミラー市場は、特定の地域でヒュミラの特許が失効したことにより、他の製薬会社が市場に参入し、より手頃な価格のヒュミラを製造できるようになったため、大きな成長を遂げています。バイオシミラーは、基準薬に代わる費用対効果の高い代替品を提供することで、患者にとって治療がより身近なものとなり、ヘルスケア支出の削減につながります。さらに、自己免疫疾患の有病率の増加と生物学的製剤による治療に対する需要の高まりが、ヒュミラのバイオシミラーの需要に拍車をかけています。
  • 世界中で、自己免疫疾患の増加やそれに伴うヘルスケア支出の急増を受け、研究・診断機関は政府機関と連携した取り組みを行っています。米国国立衛生研究所（NIH）のデータによると、自己免疫疾患は女性の死亡率上昇の原因上位10位に入っています。その結果、これらの健康課題に対処するため、研究機関や政府機関の協力による取り組みが行われています。

ヒュミラ・バイオシミラー市場-セグメンテーション分析：

  • ヒュミラ・バイオシミラー世界市場は、製品、適応症、地域によって区分されます。
  • ヒュミラのバイオシミラー市場は、製品、適応症、地域によって区分される：リファレンスベースのバイオシミラー、アミノ酸配列を変更したバイオシミラー、互換性のあるバイオシミラーです。2022年には、リファレンスベース・バイオシミラーが市場を独占すると予測されています。リファレンスベース・バイオシミラーは、リファレンス医薬品であるヒュミラ（アダリムマブ）と特性や性能を直接比較することによって開発されます。類似の細胞株や製法を用いて製造されるため、類似性の高い製品が得られます。
  • 市場は適応症により4つのカテゴリーに分けられる：関節リウマチ、乾癬、クローン病、その他です。関節リウマチ治療器セグメントは、収益において最大のシェアを占めると予想されています。関節リウマチは自己免疫疾患であり、身体の免疫システムが関節を包む膜の裏地である滑膜を誤って攻撃します。その結果、慢性的な炎症が起こり、関節の損傷、痛み、腫れ、こわばりを引き起こします。
  • アダリムマブはTNF-αを阻害することにより、炎症を抑制し、関節障害の進行を遅らせることで、関節リウマチの症状を緩和し、患者さんの生活の質を向上させます。ヒュミラバイオシミラー製剤は、ヒュミラ（一般名：アダリムマブ）に含まれる有効成分の類似性が高いため、関節リウマチの治療に使用されています。アダリムマブはモノクローナル抗体で、関節リウマチにおいて関節の炎症を引き起こす重要な役割を果たすタンパク質である腫瘍壊死因子α（TNF-α）を特異的に標的として阻害します。

ヒュミラ・バイオシミラー市場- 地理的洞察：

ヒュミラバイオシミラー市場は、北米、ラテンアメリカ、欧州、アジア太平洋、中東・アフリカの各地域に広く分布しています。これらの地域は、ビジネスを展開する国によってさらに分けられます。

ヒュミラ・バイオシミラー市場-競合情勢：

ヒュミラのバイオシミラー市場に参入している企業は、競争優位に立つためにさまざまな戦略を採用しています。これには、バイオシミラーの品質と有効性を確保するための広範な研究開発への投資、補完的な専門知識を活用するための戦略的提携や協力関係の構築、新市場へのアクセスのための地理的プレゼンスの拡大などが含まれます。さらに、魅力的な価格モデルと優れたアフターサービスを提供することで、より多くの顧客を獲得し、市場シェアを高めることに注力している企業もあります。

目次

第1章 ヒュミラバイオシミラー市場概要

  • 調査範囲
  • 市場推定年数

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 ヒュミラバイオシミラーの主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 今後の市場動向

第4章 ヒュミラバイオシミラー産業調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しのマッピング
  • 規制枠組みの分析

第5章 ヒュミラバイオシミラー市場：COVID-19症の影響分析

  • 新型コロナウイルス感染症以前の影響分析
  • 新型コロナウイルス感染症後の影響分析

第6章 ヒュミラバイオシミラー市場情勢

  • ヒュミラバイオシミラー市場シェア分析、2022年
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 ヒュミラバイオシミラー市場- 製品別

  • 概要
    • 製品別セグメントシェア分析
    • 参考文献に基づいたバイオシミラー
    • アミノ酸配列が修飾されたバイオシミラー
    • 互換性のあるバイオシミラー

第8章 ヒュミラバイオシミラー市場- 適応症別

  • 概要
    • 適応症別セグメントシェア分析
    • 関節リウマチ
    • 乾癬
    • クローン病
    • その他

第9章 ヒュミラバイオシミラー市場-地域

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋地域の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東とアフリカ
    • 概要
    • 中東およびアフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第10章 主要ベンダー分析- ヒュミラバイオシミラー業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Amgen
    • Samsung Bioepis
    • Sandoz（a division of Novartis）
    • Mylan（now part of Viatris）
    • Boehringer Ingelheim
    • Pfizer
    • Fresenius Kabi
    • Coherus BioSciences
    • Merck &Co.

第11章 アナリストの全方位展望

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Humira Biosimilar Market: Product Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Product
  • TABLE Global Humira Biosimilar Market, by Product 2018-2030 (USD Million)
  • TABLE Humira Biosimilar Market: Indication Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Indication
  • TABLE Global Humira Biosimilar Market, by Indication 2018-2030 (USD Million)
  • TABLE Humira Biosimilar Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Humira Biosimilar Market, by Region 2018-2030 (USD Million)
  • TABLE North America Humira Biosimilar Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Humira Biosimilar Market, by Product, 2018-2030 (USD Million)
  • TABLE North America Humira Biosimilar Market, by Indication, 2018-2030 (USD Million)
  • TABLE Europe Humira Biosimilar Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Humira Biosimilar Market, by Product, 2018-2030 (USD Million)
  • TABLE Europe Humira Biosimilar Market, by Indication, 2018-2030 (USD Million)
  • TABLE Asia Pacific Humira Biosimilar Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Humira Biosimilar Market, by Product, 2018-2030 (USD Million)
  • TABLE Asia Pacific Humira Biosimilar Market, by Indication, 2018-2030 (USD Million)
  • TABLE Latin America Humira Biosimilar Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Humira Biosimilar Market, by Product, 2018-2030 (USD Million)
  • TABLE Latin America Humira Biosimilar Market, by Indication, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Humira Biosimilar Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Humira Biosimilar Market, by Product, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Humira Biosimilar Market, by Indication, 2018-2030 (USD Million)

List of Figures

  • FIGURE Humira Biosimilar Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Product segment market share analysis, 2022 & 2030
  • FIGURE Product segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indication segment market share analysis, 2022 & 2030
  • FIGURE Indication segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022 & 2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Humira Biosimilar Market share and leading players, 2022
  • FIGURE Europe Humira Biosimilar Market share and leading players, 2022
  • FIGURE Asia Pacific Humira Biosimilar Market share and leading players, 2022
  • FIGURE Latin America Humira Biosimilar Market share and leading players, 2022
  • FIGURE Middle East and Africa Humira Biosimilar Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Humira Biosimilar Market share analysis by country, 2022
  • FIGURE Germany Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Humira Biosimilar Market share analysis by country, 2022
  • FIGURE India Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Humira Biosimilar Market share analysis by country, 2022
  • FIGURE Brazil Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Humira Biosimilar Market share analysis by country, 2022
  • FIGURE Saudi Arabia Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Humira Biosimilar Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
目次
Product Code: ANV1743

REPORT HIGHLIGHT

Humira Biosimilar Market size was valued at USD 790.1 Million in 2022, expanding at a CAGR of 20.9% from 2023 to 2030

Humira biosimilars are biologic drugs that are highly similar to the reference biologic drug Humira (adalimumab). Adalimumab is a monoclonal antibody that targets tumor necrosis factor alpha (TNF-α) and is used to treat various autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. Biosimilars are developed to be comparable in terms of safety, efficacy, and quality to the original drug but are manufactured by different companies after the patent of the reference drug has expired.

Humira Biosimilar Market - Market Dynamics:

  • Increasing prevalence of autoimmune diseases and the rising demand for biologic treatments
  • The Humira biosimilar market is experiencing significant growth due to the expiration of Humira's patents in certain regions, allowing other pharmaceutical companies to enter the market and produce more affordable versions of the drug. Biosimilars offer cost-effective alternatives to the reference drug, making treatment more accessible to patients and reducing healthcare expenditures. Additionally, the increasing prevalence of autoimmune diseases and the rising demand for biologic treatments have fueled the demand for Humira biosimilars.
  • Across the globe, research and diagnostic institutes are engaging in initiatives aligned with government organizations due to the increasing occurrence of autoimmune disorders and the subsequent surge in healthcare spending. The National Institutes of Health (NIH) data reveals that autoimmune disorders rank among the top ten causes of heightened mortality rates in women. As a result, concerted efforts are being made to address these health challenges through collaborative endeavors between institutes and government bodies.

Humira Biosimilar Market - Key Insights:

  • As per the analysis shared by our research analyst, the global Humira Biosimilar market is estimated to grow annually at a CAGR of around 20.9% over the forecast period (2023-2030)
  • The Humira Biosimilar industry is projected to grow at a significant rate due to increasing prevalence of autoimmune diseases and the rising demand for biologic treatments
  • Based on Indication type segmentation, Rheumatoid arthritis was predicted to show maximum market share in the year 2022
  • Based on Product segmentation, Reference-Based Biosimilars was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

Humira Biosimilar Market- Segmentation Analysis:

  • The Global Humira Biosimilar Market is segmented on the basis of Product, Indication, and Region.
  • The market is divided into three categories based on Product: Reference-Based Biosimilars, Biosimilars with Modified Amino Acid Sequences and Interchangeable Biosimilars . In 2022, the Reference-Based Biosimilars segment is projected to dominate the market Reference-Based Biosimilars are developed by directly comparing their characteristics and performance to the reference drug, Humira (adalimumab). They are manufactured using similar cell lines and processes to produce a highly similar product.
  • The market is divided into four categories based on Indication: Rheumatoid arthritis, psoriasis, Crohn's disease and others. The Rheumatoid arthritis equipment segment is anticipated to hold the largest share in revenue. Rheumatoid arthritis is autoimmune disease in which the body's immune system mistakenly attacks the synovium, which is the lining of the membranes that surround the joints. This results in chronic inflammation, leading to joint damage, pain, swelling, and stiffness.
  • By blocking TNF-α, adalimumab helps to reduce inflammation and slow down the progression of joint damage, thereby providing relief from the symptoms of rheumatoid arthritis and improving the patient's quality of life. Humira biosimilars are used in the treatment of rheumatoid arthritis because they contain a highly similar version of the active ingredient found in the reference drug Humira (adalimumab). Adalimumab is a monoclonal antibody that specifically targets and inhibits tumor necrosis factor alpha (TNF-α), a protein that plays a key role in causing inflammation in the joints in rheumatoid arthritis.

Humira Biosimilar Market - Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Humira Biosimilar Market- Competitive Landscape:

Companies in the Humira biosimilar market are adopting various strategies to gain a competitive edge. These include investing in extensive research and development to ensure the quality and efficacy of their biosimilars, forming strategic partnerships or collaborations to leverage complementary expertise, and expanding their geographic presence to access new markets. Moreover, some companies focus on offering attractive pricing models and excellent after-sales support to attract more customers and enhance their market share.

Recent Developments:

In September 2016, Amjevita (adalimumab-atto) achieved the distinction of being the first FDA-approved biosimilar for Humira. Subsequently, on January 31, 2023, it marked another milestone by becoming the first Humira biosimilar to be launched in the United States. Amjevita is among the approved Humira biosimilars that have received regulatory clearance for treating HS (hidradenitis suppurativa) in adults.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL HUMIRA BIOSIMILAR MARKET KEY PLAYERS

  • Amgen
  • Samsung Bioepis
  • Sandoz (a division of Novartis)
  • Mylan (now part of Viatris)
  • Boehringer Ingelheim
  • Pfizer
  • Fresenius Kabi
  • Coherus BioSciences
  • Merck & Co.

GLOBAL HUMIRA BIOSIMILAR MARKET, BY PRODUCT

  • Reference-Based Biosimilars
  • Biosimilars with Modified Amino Acid Sequences
  • Interchangeable Biosimilars

GLOBAL HUMIRA BIOSIMILAR MARKET, BY INDICATION

  • Rheumatoid arthritis
  • Psoriasis
  • Crohn's disease
  • Others

GLOBAL HUMIRA BIOSIMILAR MARKET, BY REGION

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Humira Biosimilar Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Humira Biosimilar Market Snippet by Product
    • 2.1.2. Humira Biosimilar Market Snippet by Indication
    • 2.1.3. Humira Biosimilar Market Snippet by Country
    • 2.1.4. Humira Biosimilar Market Snippet by Region
  • 2.2. Competitive Insights

3. Humira Biosimilar Key Market Trends

  • 3.1. Humira Biosimilar Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Humira Biosimilar Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Humira Biosimilar Market Opportunities
  • 3.4. Humira Biosimilar Market Future Trends

4. Humira Biosimilar Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Humira Biosimilar Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Humira Biosimilar Market Landscape

  • 6.1. Humira Biosimilar Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Humira Biosimilar Market - By Product

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product, 2022 & 2030 (%)
    • 7.1.2. Reference-Based Biosimilars
    • 7.1.3. Biosimilars with Modified Amino Acid Sequences
    • 7.1.4. Interchangeable Biosimilars

8. Humira Biosimilar Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2022 & 2030 (%)
    • 8.1.2. Rheumatoid arthritis
    • 8.1.3. Psoriasis
    • 8.1.4. Crohn's disease
    • 8.1.5. Others

9. Humira Biosimilar Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Humira Biosimilar Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Humira Biosimilar Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.3.7. Italy
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.7.3. Italy Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.3.7.4. Italy Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.3.8. United Kingdom
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.8.3. United Kingdom Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.3.8.4. United Kingdom Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.3.9. France
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.9.3. France Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.3.9.4. France Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.3.10. Russia
      • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.10.2. Russia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.3.10.3. Russia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.3.11. Netherlands
      • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.11.2. Netherlands Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.3.11.3. Netherlands Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.12.2. Sweden Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.3.13. Poland
      • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.13.2. Poland Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.3.13.3. Poland Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.3.14. Rest of Europe
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Humira Biosimilar Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.4.6. India
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.6.3. India Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.4.6.4. India Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.4.7. China
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.7.3. China Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.4.7.4. China Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.4.11. Thailand
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.11.3. Thailand Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.4.11.4. Thailand Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.4.12. Indonesia
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.12.3. Indonesia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.4.12.4. Indonesia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Humira Biosimilar Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.5.5. Latin America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Humira Biosimilar Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.6.7. United Arab Emirates
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Product, 2018 - 2030 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Humira Biosimilar Industry

  • 10.1. Competitive Dashboard
  • 10.2. Company Profiles
    • 10.2.1. Amgen
    • 10.2.2. Samsung Bioepis
    • 10.2.3. Sandoz (a division of Novartis)
    • 10.2.4. Mylan (now part of Viatris)
    • 10.2.5. Boehringer Ingelheim
    • 10.2.6. Pfizer
    • 10.2.7. Fresenius Kabi
    • 10.2.8. Coherus BioSciences
    • 10.2.9. Merck & Co.

11. 360 Degree Analyst View

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us